Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 28, 2020
Daily News
April 28, 2020
- Sumitomo Dainippon, Nihon Generic Pulling Some Metformin Products over Carcinogen Risks
April 28, 2020
- Daiichi Sankyo Sees 30% Growth for Edoxaban, Strong Enhertu Uptick in FY2019
April 28, 2020
- Antigen Test for New Coronavirus Filed in Japan: Minister
April 28, 2020
- GSK, MICIN to Test Online Medical Exams and Medication Guidance for Improving Adherence in Asthma Patients
April 28, 2020
- Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
- Over 70% of Pharmacists Have “No Trouble” Getting Drug Info. Since Coronavirus Outbreak: Survey
April 28, 2020
- Keio Univ. Spinout Weighs In on AnGes' COVID-19 Vaccine Initiatives
April 28, 2020
- Shionogi Aims to Begin Clinical Studies for COVID-19 Vaccine in 2020
April 28, 2020
- Janssen Files for SC Injection of Darzalex/Vorhyaluronidase Alfa Combo for MM in Japan
April 28, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…